Mutation analysis of the checkpoint kinase 2 gene in colorectal cancer cell lines

Chinese Medical Journal

Volumn 120, Issue 23, 2007, Pages 2119-2123

  Liu, Wei Dong ^a   Zhong, Bai Yun ^a   Zhang, Yang De ^a   Choi, Gyu Seog ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Kyungpook National University Hospital   (South Korea)

Author keywords

Cell line, colorectal cancer; Checkpoint kinase 2; Colorectal cancer; Denaturing high performance liquid chromatography

Indexed keywords

ARGININE; CHECKPOINT KINASE 2; CYTOSINE; THYMINE; TRYPTOPHAN;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CELL MUTANT; COLORECTAL CANCER; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; EXON; GENE AMPLIFICATION; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; HUMAN CELL; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE;

EID: 37249050886     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200712010-00010     Document Type: Article

References (34)

1. de Jong MM, Nolte IM, Te Meerman GJ, van der Graaf WT, Mulder MJ, van der Steege G, et al. Colorectal cancer and the CHEK2 1100delC mutation. Genes Chromosomes Cancer 2005; 43: 377-382.
2. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002; 71: 432-438.
3. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55-59.
4. CHEK2-Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004; 74: 1175-1182.
5. Blasina A, de Weyer IV, Laus MC, Luyten WH, Parker AE, McGowan CH. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr Biol 1999; 9: 1-10.
6. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM-CHK2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001; 410: 842-847.
7. Tominaga K, Morisaki H, Kaneko Y, Fujimoto A, Tanaka T, Ohtsubo M, et al. Role of human Cds1 (CHK2) kinase in DNA damage checkpoint and its regulation by p53. J Biol Chem 1999, 274: 31463-31467.
8. Chehab NH, Malikzay A, Appel M, Halazonetis TD. CHK2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 2000; 14:278-288.
9. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000; 404: 201-204.
10. Pommier Y, Weinstein JN, Aladjeni MI, Kohn KW. CHK2 molecular interaction map and rationale for CHK2 inhibitors. Clin Cancer Res 2006; 12: 2657-2661.
11. Pommier Y, Sordet O, Rao VA, Zhang H, Kohn KW. Targeting CHK2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des 2005; 11: 2855-2872.
12. van Puijenbroek M, van Asperen CJ, van Mil A, Devilee P, van Wezel T, Morreau H. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype. J Pathol 2005; 206: 198-204.
13. Sanchez de Abajo A, de la. Hoya M, Godino J, Furio V, Tosar A, Perez-Segura P, et al. The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families. Fam Cancer 2005; 4: 183-186.
14. Kilpivaara O, Laiho P, Aaltonen LA, Nevanlinna H. CHEK2 1100delC and colorectal cancer. J Med Genet 2003; 40: e110.
15. Luciani MG; Campregher C, Fortune JM, Kunkel TA, Gasche C. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007; 132: 221-235.
16. Liu X, Bian C, Ren K, Jin H, Li B, Shao RG. Lidamycin induces marked G2 cell cycle arrest in human colon carcinoma HT-29 cells through activation of p38 MAPK pathway. Oncol Rep 2007; 17: 597-603.
17. Williams LH, Choong D, Johnson SA, Campbell IG. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin Cancer Res 2006; 12: 6967-6972.
18. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429.
19. Evans SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 1997; 3: 390-395.
20. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Lubratovich M, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286: 2528-2531.
21. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, et al. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 2003; 72: 1308-1314.
22. Lipton L, Fleischmann C, Sieber OM, Thomas HJ, Hodgson SV, Tomlinson IP, et al. Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma. Cancer Lett 2003; 200: 149-152.
23. Wu X, Webster SR, Chen J. Characterization of tumor-associated CHK2 mutations. J Biol Chem 2001; 276: 2971-2974.
24. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998; 392: 300-303.
25. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-649.
26. DiTullio RA Jr, Mochan TA, Vencre M, Bartkova J, Sehested M, Bartek J, et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 2002; 4: 998-1002.
27. Lukas C, Falck J, Bartkova J, Bartek J, Lukas J. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol 2003; 5: 255-260.
28. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-870.
29. Ahn J, Urist M, Prives C. Questioning the role of checkpoint kinase 2 in the p53 DNA damage response. J Biol Chem 2003; 278: 20480-20489.
30. Parsels LA, Parsels JD, Tai DC, Coughlin DJ, Maybaum J. 5-fluoro-2′-deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells. Cancer Res 2004; 64: 6588-6594.
31. Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol 2000; 46: 507-516.
32. Takemura H, Rao VA, Sordet O, Furuta T, Miao ZH, Meng L, et al. Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to repjication-dependent DNA double strand breaks. J Biol Chem 2006; 281: 30814-30823.
33. Flatten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM, et al. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 2005; 280: 14349-14355.
34. Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, Takemura H, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 2003; 532: 173-203.